IDO inhibitors are used as a method to reverse the immunosuppressive effect of regionally expressed indoleamine 2,3-dioxygenase 1 (IDO1) at the tumour site, which usually impedes T-cells maturation by interfering with the kynurenine pathway. The gene discussed is IDO1; the disease is neoplasm.